Profile data is unavailable for this security.
About the company
Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.
- Revenue in USD (TTM)0.00
- Net income in USD-12.48m
- Incorporated2008
- Employees4.00
- LocationQualigen Therapeutics Inc1880 Century Park E Ste 1000LOS ANGELES 90067-1623United StatesUSA
- Phone+1 (310) 203-1000
- Fax+1 (310) 919-1600
- Websitehttps://www.qualigeninc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Virpax Pharmaceuticals Inc | 0.00 | -16.89m | 1.48m | 7.00 | -- | -- | -- | -- | -14.42 | -14.42 | 0.00 | -1.04 | 0.00 | -- | -- | 0.00 | -156.21 | -87.52 | -241.52 | -116.56 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.84 | -- | -- | -- |
| 180 Life Sciences Corp | 0.00 | -16.24m | 1.53m | 4.00 | -- | -- | -- | -- | -41.54 | -41.54 | 0.00 | -1.12 | 0.00 | -- | -- | 0.00 | -176.90 | -42.39 | -354.57 | -56.41 | -- | -- | -- | -- | -- | -385.88 | -- | -- | -- | -- | 48.52 | -- | -- | -- |
| Bluejay Diagnostics Inc | 0.00 | -9.74m | 1.54m | 10.00 | -- | 0.4232 | -- | -- | -7.68 | -7.68 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -122.06 | -- | -149.68 | -- | -- | -- | -- | -- | -- | -- | 0.0048 | -- | -100.00 | -- | -7.07 | -- | -- | -- |
| Finch Therapeutics Group Inc | 0.00 | -16.28m | 1.55m | 18.00 | -- | 0.0816 | -- | -- | -10.14 | -10.14 | 0.00 | 11.86 | 0.00 | -- | -- | -- | -25.22 | -- | -28.97 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| InVitro International | 716.89k | 6.22k | 1.57m | 16.00 | 197.34 | 2.15 | -- | 2.19 | 0.0004 | 0.0004 | 0.0402 | 0.0321 | 1.15 | -- | -- | -- | 0.995 | 7.89 | 1.09 | 8.83 | -- | -- | 0.8676 | 5.90 | -- | -- | -- | -- | -5.11 | 1.33 | -87.77 | -16.14 | -- | -- |
| Target Group Inc | 5.64m | 228.87k | 1.57m | 46.00 | 19.62 | -- | 1.48 | 0.279 | 0.0001 | 0.0001 | 0.0088 | -0.0115 | 0.764 | 8.60 | 124.27 | 115,104.10 | 3.10 | -37.99 | -- | -78.76 | 43.71 | -- | 4.06 | -586.97 | 0.0736 | 0.0149 | 3.10 | -- | -- | 577.83 | 92.84 | -- | -58.54 | -- |
| Mallinckrodt PLC | 1.91bn | -1.49bn | 1.60m | 2.80k | -- | -- | -- | 0.0008 | -161.65 | -161.63 | 89.63 | 55.44 | 0.4062 | 1.57 | 4.94 | 681,821.40 | -31.61 | -12.49 | -36.10 | -15.85 | 26.22 | 35.68 | -77.83 | -44.38 | 1.63 | -0.3456 | 0.6164 | -- | -2.53 | -10.31 | -83.00 | -- | -- | -- |
| Procyon Corp | 4.77m | -387.79k | 1.62m | 17.00 | -- | 0.764 | -- | 0.3397 | -0.0478 | -0.0478 | 0.5891 | 0.2774 | 1.39 | 1.94 | 9.60 | 280,817.70 | -10.81 | 3.52 | -13.69 | 4.23 | 78.01 | 73.30 | -7.78 | 2.52 | 2.22 | -- | 0.00 | -- | -3.22 | 3.11 | 70.44 | -- | 30.98 | -- |
| Stemcell Holdings Inc | 9.98m | 3.10m | 1.64m | -- | -- | -- | 0.5008 | 0.1645 | 0.00008 | 0.00008 | 0.0003 | 0.0002 | 1.12 | -- | 5.20 | -- | 34.90 | -- | 68.19 | -- | 77.19 | -- | 31.04 | -- | -- | -- | 0.00 | -- | 85.10 | -- | 71.82 | -- | -- | -- |
| Dermata Therapeutics Inc | 0.00 | -8.69m | 1.70m | 8.00 | -- | 6.71 | -- | -- | -24.67 | -24.67 | 0.00 | 0.5717 | 0.00 | -- | -- | 0.00 | -120.05 | -- | -146.08 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.90 | -- | -- | -- |
| Qualigen Therapeutics Inc | 0.00 | -12.48m | 1.70m | 4.00 | -- | -- | -- | -- | -2.46 | -2.64 | 0.00 | -0.3923 | 0.00 | -- | -- | 0.00 | -118.15 | -- | -364.72 | -- | 21.30 | -- | -- | -- | -- | -7.41 | -- | -- | -- | -- | 10.22 | -- | -- | -- |
| PainReform Ltd | 0.00 | -12.54m | 1.76m | 6.00 | -- | 0.7109 | -- | -- | -7.77 | -7.77 | 0.00 | 0.9988 | 0.00 | -- | -- | 0.00 | -158.88 | -55.47 | -222.89 | -68.20 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.28 | -- | -- | -- |
| Hi-Great Group Holding Co | 109.49k | -121.76k | 1.78m | -- | -- | -- | -- | 16.26 | -0.0012 | -0.0012 | 0.0011 | -0.0011 | 0.8224 | 0.8406 | -- | -- | -91.46 | -- | -- | -- | 46.50 | -- | -111.21 | -- | 0.0144 | -52.41 | -- | -- | -47.32 | -- | -3,789.70 | -- | -- | -- |
| SYBLEU Inc | 11.70k | -307.88k | 1.84m | -- | -- | -- | -- | 157.17 | -0.0293 | -0.0293 | 0.0011 | -0.0367 | 0.0641 | -- | -- | -- | -168.63 | -- | -- | -- | -- | -- | -2,631.45 | -- | -- | -8.48 | 4.96 | -- | 0.00 | -- | 26.51 | -- | -- | -- |
| SOHM Inc | -100.00bn | -100.00bn | 1.84m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| CanaQuest Medical Corp | 0.00 | -808.07k | 1.92m | -- | -- | -- | -- | -- | -0.0514 | -0.0514 | 0.00 | -0.037 | 0.00 | -- | -- | -- | -1,084.38 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 57.42 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Qualigen Therapeutics Inc's reporting currency: US Dollar USD
4.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Citadel Securities LLCas of 31 Mar 2024 | 57.18k | 0.91% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 42.97k | 0.68% |
| Geode Capital Management LLCas of 31 Mar 2024 | 41.90k | 0.66% |
| Virtu Americas LLCas of 31 Mar 2024 | 27.55k | 0.44% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 25.61k | 0.41% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 22.83k | 0.36% |
| HRT Financial LLCas of 31 Mar 2024 | 12.50k | 0.20% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 11.92k | 0.19% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 10.93k | 0.17% |
| XTX Markets LLCas of 31 Mar 2024 | 10.85k | 0.17% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
